Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK | Market Cap | 124.55B +24.5% |
| Revenue (ttm) | 24.48B +29.6% |
| Net Income | 10.08B +125.1% |
| EPS | 159.78 +132.4% |
| Shares Out | 61.60M |
| PE Ratio | 12.65 |
| Forward PE | 15.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 139,686 |
| Average Volume | 120,203 |
| Open | 2,045.00 |
| Previous Close | 2,067.00 |
| Day's Range | 2,022.00 - 2,079.00 |
| 52-Week Range | 1,157.00 - 2,257.00 |
| Beta | 0.79 |
| RSI | 44.70 |
| Earnings Date | Feb 17, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.
Financial numbers in USD Financial StatementsNews
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; January 29, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to...
Interim Results for the six months ended 31 October 2025
OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody ® and Moditope ® active immunotherapies to treat cancer, today announces a busi...
Genmab: Darzalex Growth Fuels Rally, Upside Is Tight
Genmab hits a 52-week high as Darzalex sales jump 27% YoY. See why I rate the GMAB stock a Hold.
Independence Bank of Kentucky Buys 34 Shares of Genmab AS (GMAB)
Independence Bank of Kentucky Buys 34 Shares of Genmab AS (GMAB)
Genmab Announces 23% Annual Increase In 2025 DARZALEX Sales
(RTTNews) - Genmab A/S (GMAB) reported another year of rising global sales for its flagship antibody therapy DARZALEX (daratumumab), with 2025 net trade sales reaching $14.35 billion according to figu...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
Company Announcement Net sales of DARZALEX ® in 2025 totaled USD 14,351 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENH...
Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside
On Friday, Genmab A/S (NASDAQ: GMAB) released topline results from the Phase 3 EPCORE DLBCL-1 trial of epcoritamab for diffuse large B-cell lymphoma (DLBCL). The trial evaluated epcoritamab to the in...
Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside
On Friday, Genmab A/S (NASDAQ: GMAB) released topline results from the Phase 3 EPCORE DLBCL-1 trial of epcoritamab for diffuse large B-cell lymphoma (DLBCL).
Genmab (GMAB) Receives Maintained 'Buy' Rating Amid Price Target Revision | GMAB Stock News
Genmab (GMAB) Receives Maintained 'Buy' Rating Amid Price Target Revision | GMAB Stock News
AbbVie And Genmab: Phase 3 EPCORE DLBCL-1 Trial Shows PFS Gains But No Significant OS Benefit
(RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) released results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a subcutaneously administered, T-cell engaging bispecific antibody, versu...
Genmab (GMAB) Phase 3 Trial Results: Impact and Future Outlook
Genmab (GMAB) Phase 3 Trial Results: Impact and Future Outlook
Genmab's (GMAB) Epcoritamab Shows Promise in DLBCL Trial
Genmab's (GMAB) Epcoritamab Shows Promise in DLBCL Trial
Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma
AbbVie (ABBV) and Genmab Advance Epcoritamab Trials for Lymphoma
AbbVie (ABBV) and Genmab Advance Epcoritamab Trials for Lymphoma
Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study
Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood cancer failed to improve the survival rate in patients in a late-stage study.
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody admi...
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Company Announcement Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab...
Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-14. The following slide deck was published by Genmab A/S in conjunction with this event.
Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Genmab A/S at JPMorgan Healthcare Conference Transcript
Genmab A/S at JPMorgan Healthcare Conference Transcript
LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Genmab AS (OCSE:GMAB)
LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Genmab AS (OCSE:GMAB)
Genmab: AI Partnership And Clinical Data Fuel Growth
Genmab shifts to innovation-led growth with 21% revenue, 52% operating profit, $3.4B cash, Epkinly, Rina-S, and Anthropic AI R&D. See why GMAB stock is a buy.
Why Are Investors Paying Attention To Genmab Stock?
Shares of Genmab (NASDAQ: GMAB) are rising ... Full story available on Benzinga.com
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
Media Release COPENHAGEN, Denmark; January 07, 2026 Supports Genmab's ambition to build an AI-enabled innovation model that advances the company's vision of bringing transformative antibody medicines ...